These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study. Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661 [TBL] [Abstract][Full Text] [Related]
6. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke. Nasir UB; Qureshi WT; Jogu H; Wolfe E; Dutta A; Majeed CN; Tan WA Cardiovasc Revasc Med; 2019 Mar; 20(3):187-193. PubMed ID: 30905408 [TBL] [Abstract][Full Text] [Related]
10. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132 [TBL] [Abstract][Full Text] [Related]
11. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. Mas JL; Derumeaux G; Amarenco P; Arquizan C; Aubry P; Barthelet M; Bertrand B; Brochet E; Cabanes L; Donal E; Dubois-Randé JL; Durand-Zaleski I; Ernande L; Finet G; Fraisse A; Giroud M; Guérin P; Habib G; Juliard JM; Leys D; Lièvre M; Lusson JR; Marcon F; Michel P; Moulin T; Mounier-Vehier F; Pierard L; Piot C; Rey C; Rodier G; Roudaut R; Schleich JM; Teiger E; Turc G; Vuillier F; Weimar C; Woimant F; Chatellier G; Int J Stroke; 2016 Aug; 11(6):724-32. PubMed ID: 27056964 [TBL] [Abstract][Full Text] [Related]
12. [Closure of the patent foramen ovale (PFO) in cryptogenic stroke]. Diener HC; Knebel F Herz; 2019 Jun; 44(4):304-309. PubMed ID: 30941472 [TBL] [Abstract][Full Text] [Related]
13. Secondary Stroke Prevention Following Embolic Stroke of Unknown Source in the Absence of Documented Atrial Fibrillation: A Clinical Review. Kotadia ID; Sim I; Mukherjee R; O'Hare D; Chiribiri A; Birns J; Bhalla A; O'Neill M; Williams SE J Am Heart Assoc; 2021 Jul; 10(13):e021045. PubMed ID: 34212774 [TBL] [Abstract][Full Text] [Related]
14. Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS). Diener HC; Bernstein R; Hart R Curr Neurol Neurosci Rep; 2017 Sep; 17(9):64. PubMed ID: 28707135 [TBL] [Abstract][Full Text] [Related]
15. [Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke]. Donti A; Egidy Assenza G; Mariucci E G Ital Cardiol (Rome); 2019 Feb; 20(2):73-84. PubMed ID: 30747923 [TBL] [Abstract][Full Text] [Related]
16. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors. Verma N; Ziegler PD; Liu S; Passman RS Int J Stroke; 2019 Feb; 14(2):146-153. PubMed ID: 30196791 [TBL] [Abstract][Full Text] [Related]
17. Medical Management for Secondary Stroke Prevention. Kim AS Continuum (Minneap Minn); 2020 Apr; 26(2):435-456. PubMed ID: 32224760 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke. Smer A; Salih M; Mahfood Haddad T; Guddeti R; Saadi A; Saurav A; Belbase R; Ayan M; Traina M; Alla V; Del Core M Am J Cardiol; 2018 Jun; 121(11):1393-1399. PubMed ID: 29680170 [TBL] [Abstract][Full Text] [Related]